Journey Medical Corp (DERM)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
DERM
Journey Medical Corp
$6.15
-2.54%
HEALTHCARE · Cap: $181.18M
TAK
Takeda Pharmaceutical Co Ltd ADR
$17.25
-2.82%
HEALTHCARE · Cap: $55.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 6966072% more annual revenue ($4.51T vs $64.68M). TAK leads profitability with a -3.4% profit margin vs -14.8%. TAK earns a higher WallStSmart Score of 57/100 (C).
DERM
Avoid28
out of 100
Grade: F
TAK
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-66.8%
Fair Value
$4.79
Current Price
$6.15
$1.36 premium
Intrinsic value data unavailable for TAK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 21.5% year-over-year
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 330.2% YoY
Large-cap with strong market position
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -31.1% — below average capital efficiency
3.9% revenue growth
ROE of 2.5% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : DERM
The strongest argument for DERM centers on Revenue Growth. Revenue growth of 21.5% demonstrates continued momentum.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.45 suggests the stock is reasonably priced for its growth.
Bear Case : DERM
The primary concerns for DERM are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, Return on Equity, Free Cash Flow.
Key Dynamics to Monitor
DERM profiles as a growth stock while TAK is a turnaround play — different risk/reward profiles.
DERM carries more volatility with a beta of 1.07 — expect wider price swings.
DERM is growing revenue faster at 21.5% — sustainability is the question.
DERM generates stronger free cash flow (3M), providing more financial flexibility.
Bottom Line
TAK scores higher overall (57/100 vs 28/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Journey Medical Corp
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Dermira, Inc., a biopharmaceutical company, develops and markets therapies for patients with dermatological diseases in the United States.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?